CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT
ANTIBODY-DRUG CONJUGATE SYS6023 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the antibody-drug conjugate SYS6023 (the "**Product**") developed by CSPC Megalith Biopharmaceutical Co., Ltd.* (石藥集團巨石生物製藥有限公司), a subsidiary of the Group, has obtained approval of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the United States (the "**U.S.**"). Previously, the Product has obtained clinical trial approval granted by the National Medical Products Administration of the People's Republic of China to conduct clinical trials in China in March 2024.

SYS6023 is a monoclonal antibody-drug conjugate which can bind to specific receptors on the tumor surface and achieve tumor cell killing by entering the cells through endocytosis and releasing toxins. The indications for this clinical trial approval are advanced solid tumors. Preclinical studies have demonstrated that the Product has good anti-tumor effects on a variety of cancers, providing promising clinical development values. A number of patent applications of the Product have been submitted.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 8 July 2024

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. JIANG Hao, Dr. YAO Bing and Mr. CAI Xin as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.

* *for identification purpose only*